The SAMe-TT2R2 Score Predicts Warfarin Control in an Australian Population with Atrial Fibrillation
Abstract
1. Introduction
2. Materials and Methods
2.1. Data Collection
2.2. Statistical Analyses
3. Results
4. Discussion
5. Conclusions
Author Contributions
Acknowledgments
Conflicts of Interest
References
- Nutescu, E.A. Oral anticoagulant therapies: Balancing the risks. Am. J. Health Syst. Pharm. 2013, 70 (Suppl. 1), S3–S11. [Google Scholar] [CrossRef] [PubMed]
- Navgren, M.; Forsblad, J.; Wieloch, M. Bleeding complications related to warfarin treatment: A descriptive register study from the anticoagulation clinic at Helsingborg Hospital. J. Thromb. Thrombolysis 2014, 38, 98–104. [Google Scholar] [CrossRef] [PubMed]
- Bauer, K.A. Pros and cons of new oral anticoagulants. Hematol. Am. Soc. Hematol. Educ. Program 2013, 2013, 464–470. [Google Scholar] [CrossRef]
- Brieger, D.; Amerena, J.; Attia, J.; Bajorek, B.; Chan, K.H.; Connell, C.; Freedman, B.; Ferguson, C.; Hall, T.; Haqqani, H.M.; et al. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation. Heart Lung Circ. 2018, 27, 1209–1266. [Google Scholar] [CrossRef] [PubMed]
- Bernaitis, N.; Badrick, T.; Davey, A.K.; Crilly, J.; Anoopkumar-Dukie, S. Warfarin control in patients transitioning to warfarin after non-vitamin K oral anticoagulant (NOAC) therapy. J. Thromb. Thrombolysis 2018, 46, 461–465. [Google Scholar] [CrossRef] [PubMed]
- Morgan, C.L.; McEwan, P.; Tukiendorf, A.; Robinson, P.A.; Clemens, A.; Plumb, J.M. Warfarin treatment in patients with atrial fibrillation: Observing outcomes associated with varying levels of INR control. Thromb. Res. 2009, 124, 37–41. [Google Scholar] [CrossRef] [PubMed]
- Shields, A.M.; Lip, G.Y. Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation. J. Intern. Med. 2015, 278, 1–18. [Google Scholar] [CrossRef]
- Mueller, K.; Bernaitis, N.; Badrick, T.; Anoopkumar-Dukie, S. HAS-BLED predicts warfarin control in Australian patients treated for deep vein thrombosis. Basic Clin. Pharmacol. Toxicol. 2017, 120, 299–302. [Google Scholar] [CrossRef] [PubMed]
- Bernaitis, N.; Ching, C.K.; Badrick, T.; Anoopkumar-Dukie, S. Identifying warfarin control with stroke and bleed risk scores. Heart Lung Circ. 2018, 27, 756–759. [Google Scholar] [CrossRef]
- Rose, A.J.; Hylek, E.M.; Ozonoff, A.; Ash, A.S.; Reisman, J.I.; Berlowitz, D.R. Patient characteristics associated with oral anticoagulation control: Results of the veterans affairs study to improve anticoagulation (VARIA). J. Thromb. Haemost. 2010, 8, 2182–2191. [Google Scholar] [CrossRef] [PubMed]
- Williams, B.A.; Evans, M.A.; Honushefsky, A.M.; Berger, P.B. Clinical prediction model for time in therapeutic range while on warfarin in newly diagnosed atrial fibrillation. J. Am. Heart Assoc. 2017, 6, e006669. [Google Scholar] [CrossRef] [PubMed]
- Lin, K.J.; Singer, D.E.; Glynn, R.J.; Blackley, S.; Zhou, L.; Liu, J.; Dube, G.; Oertel, L.B.; Schneeweiss, S. Prediction score for anticoagulation control quality among older adults. J. Am. Heart Assoc. 2017, 6, e006814. [Google Scholar] [CrossRef] [PubMed]
- Apostolakis, S.; Sullivan, R.M.; Olshansky, B.; Lip, G.Y. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: The SAMe-TT2R2 score. Chest 2013, 144, 1555–1563. [Google Scholar] [CrossRef] [PubMed]
- Kirchhof, P.; Benussi, S.; Kotecha, D.; Ahlsson, A.; Atar, D.; Casadei, B.; Castellá, M.; Diener, H.C.; Heidbuchel, H.; Hendriks, J.; et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. J. Cardio Thorac. Surg. 2016, 37, 2893–2962. [Google Scholar]
- Chiang, C.-E.; Okumura, K.; Zhang, S.; Chao, T.-F.; Siu, C.-W.; Lim, T.W.; Saxena, A.; Takahashi, Y.; Siong, W. 2017 consensus of the Asia pacific heart rhythm society on stroke prevention in atrial fibrillation. J. Arrhythm. 2017, 33, 345–367. [Google Scholar] [CrossRef] [PubMed]
- Chiang, C.-E.; Wu, T.-J.; Ueng, K.-C.; Chao, T.-F.; Chang, K.-C.; Wang, C.-C.; Lin, Y.-J.; Tsai, C.-T.; Liu, Y.-B.; Lee, Y.-T.; et al. 2016 guidelines of the Taiwan heart rhythm society and the Taiwan society of cardiology for the management of atrial fibrillation. J. Formos. Med. Assoc. 2016, 115, 893–952. [Google Scholar] [CrossRef] [PubMed]
- Fauchier, L.; Poli, D.; Olshansky, B. The SAMe-TT2R2 score and quality of anticoagulation in AF: Can we predict which patient benefits from anticoagulation? Thromb. Haemost. 2015, 114, 657–659. [Google Scholar] [PubMed]
- Lee, K.H.; Park, H.W.; Yoon, N.S.; Cho, J.G.; Kim, J.E.; Ahn, Y.; Jeong, M.H.; Park, J.C. Modified application of SAME-TTR scoring system in Asian patients with atrial fibrillation for the selection of oral anticoagulants. Circulation 2016, 134 (Suppl. 1), A16446. [Google Scholar]
- Gallego, P.; Roldán, V.; Marin, F.; Gálvez, J.; Valdés, M.; Vicente, V.; Gregory, Y.H. SAMe-TT 2 R 2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am. J. Med. 2014, 127, 1083–1088. [Google Scholar] [CrossRef]
- Skov, J.; Bladbjerg, E.-M.; Bor, M.V.; Gram, J. SAMeTT2R2 does not predict time in therapeutic range of the international normalized ratio in patients attending a high-quality anticoagulation clinic. Chest 2014, 145, 187–188. [Google Scholar] [CrossRef]
- Rosendaal, F.; Cannegieter, S.; Van der Meer, F.; Briet, E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb. Haemost. 1993, 69, 236–239. [Google Scholar] [CrossRef] [PubMed]
- van Miert, J.H.; Bos, S.; Veeger, N.J.; Meijer, K. Clinical usefulness of the SAMe-TT2R2 score: A systematic review and simulation meta-analysis. PloS ONE 2018, 13, e0194208. [Google Scholar] [CrossRef] [PubMed]
- Bernaitis, N.; Badrick, T.; Anoopkumar-Dukie, S. Dedicated warfarin care programme results in superior warfarin control in Queensland, Australia. Int. J. Clin. Prac. 2018, 72, e13051. [Google Scholar] [CrossRef] [PubMed]
- Bereznicki, L.R.; Madden, A.; Peterson, G.M. The quality of international normalised ratio control in southern Tasmania. Med. J. Aust. 2013, 198, 315. [Google Scholar] [CrossRef] [PubMed]
- Bernaitis, N.; Badrick, T.; Davey, A.K.; Anoopkumar-Dukie, S. Quality of warfarin control in atrial fibrillation patients in South East Queensland, Australia. Int. Med. J. 2016, 46, 925–931. [Google Scholar] [CrossRef]
- Singer, D.E.; Hellkamp, A.S.; Piccini, J.P.; Mahaffey, K.W.; Lokhnygina, Y.; Pan, G.; Halperin, J.L.; Becker, R.C.; Breithardt, G.; Hankey, G.J.; et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: Data from the ROCKET AF clinical trial. J. Am. Heart Assoc. 2013, 2, e000067. [Google Scholar] [CrossRef] [PubMed]
- Wallentin, L.; Lopes, R.D.; Hanna, M.; Thomas, L.; Hellkamp, A.; Nepal, S.; Hylek, E.M.; Al-Khatib, S.M.; Alexander, J.H.; Alings, M.; et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted INR control for stroke prevention in atrial fibrillation. Circulation 2013, 127, 2166–2176. [Google Scholar] [CrossRef] [PubMed]
- Wallentin, L.; Yusuf, S.; Ezekowitz, M.D.; Alings, M.; Flather, M.; Franzosi, M.G.; Pais, P.P.; Dans, P.A.; Eikelboom, J.; Oldgren, J.; et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: An analysis of the RE-LY trial. Lancet 2010, 376, 975–983. [Google Scholar] [CrossRef]
- Lip, G.Y.; Waldo, A.L.; Ip, J.; Martin, D.T.; Bersohn, M.M.; Choucair, W.K.; Akar, J.G.; Wathen, M.; Halperin, J.L. Determinants of time in therapeutic range in patients receiving oral anticoagulants (a substudy of IMPACT). Am. J. Cardiol. 2016, 118, 1680–1684. [Google Scholar] [CrossRef]
- Rao, S.R.; Reisman, J.I.; Kressin, N.R.; Berlowitz, D.R.; Ash, A.S.; Ozonoff, A.; Miller, D.R.; Hylek, E.M.; Zhao, S.; Rose, A.J. Explaining racial disparities in anticoagulation control: Results from a study of patients at the veterans administration. Am. J. Med. Qual. 2015, 30, 214–222. [Google Scholar] [CrossRef]
- Yong, C.; Azarbal, F.; Abnousi, F.; Heidenreich, P.A.; Schmitt, S.; Fan, J.; Than, C.T.; Ullal, A.J.; Yang, F.; Phibbs, C.S.; et al. Racial differences in quality of anticoagulation therapy for atrial fibrillation (from the TREAT-AF study). Am. J. Cardiol. 2016, 117, 61–68. [Google Scholar] [CrossRef]
- Van Spall, H.G.; Wallentin, L.; Yusuf, S.; Eikelboom, J.W.; Nieuwlaat, R.; Yang, S.; Kabali, C.; Reilly, P.A.; Ezekowitz, M.D.; Connolly, S.J. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: An analysis of patients receiving warfarin in the RE-LY trial. Circulation 2012, 126, 2309–2316. [Google Scholar] [CrossRef]
- Pickering, A.; Thomas, D.P. An audit of INR control in the Australian indigenous setting. Aust. Fam. Phys. 2007, 36, 959–960. [Google Scholar]
- Nguyen, T.; Gallagher, C.; Rocheleau, S.; Hendriks, J.; Middeldorp, M.; Mahajan, R.; Lau, D.; Nicholls, S.; Brown, A.; Sanders, P.; et al. Quality of warfarin anticoagulation for atrial fibrillation in indigenous and non-indigenous Australians. Heart Lung Circ. 2017, 26, S333–S334. [Google Scholar] [CrossRef][Green Version]
- Statistics ABO. Cultural Diversity in Australia 2016. Available online: https://www.abs.gov.au/ausstats/abs@.nsf/Lookup/by%20Subject/2071.0~2016~Main%20Features~Cultural%20Diversity%20Data%20Summary~30 (accessed on 24 May 2019).
- Tran, H.; Joseph, J.; Young, L.; McRae, S.; Curnow, J.; Nandurkar, H.; Wood, P.; McLintock, C. New oral anticoagulants: A practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Int. Med. J. 2014, 44, 525–536. [Google Scholar] [CrossRef] [PubMed]
- Zulkifly, H.; Lip, G.Y.; Lane, D.A. Use of the SAMe-TT2R2 score to predict anticoagulation control in atrial fibrillation and venous thromboembolism patients receiving vitamin K antagonists: A Review. Heart Rhythm. 2018, 15, 615–623. [Google Scholar] [CrossRef] [PubMed]
- Poli, D.; Antonucci, E.; Testa, S.; Lip, G.Y.H. A prospective validation of the SAME-TT2R2 score: How to identify atrial fibrillation patients who will have good anticoagulation control on warfarin. Int. Emerg. Med. 2014, 9, 443–447. [Google Scholar] [CrossRef] [PubMed]
- Pastori, D.; Pignatelli, P.; Cribari, F.; Carnevale, R.; Saliola, M.; Violi, F.; Lip, G.Y. Time to therapeutic range (TtTR), anticoagulation control, and cardiovascular events in vitamin K antagonists–naive patients with atrial fibrillation. Am. Heart J. 2018, 200, 32–36. [Google Scholar] [CrossRef]
- Esteve-Pastor, M.A.; Roldán, V.; Valdés, M.; Lip, G.Y.; Marín, F. The SAMe-TT2R2 score and decision-making between a vitamin K antagonist or a non-vitamin K antagonist oral anticoagulant in patients with atrial fibrillation. Expert Rev. Cardiovasc. Ther. 2016, 14, 177–187. [Google Scholar] [CrossRef]
- Proietti, M.; Lip, G.Y.H. Simple decision making between a vitamin K anatagonist and a non-vitamin K antagonist oral anticoagulant: Using the SAMe-TT2R2 score. Eur. Heart J. Cardiovasc. Pharmacother. 2015, 1, 150–152. [Google Scholar] [CrossRef][Green Version]
- Hoehmann, C.L.; Gravina, A.; Cuoco, J.A. Management of anticoagulation in rate controlled atrial fibrillation: A three step approach. Curr. Res. Cardiol. 2017, 4, 1–4. [Google Scholar] [CrossRef]
Patient Characteristic | Warfarin Care Program (n = 3911) | General Practitioner (n = 200) |
---|---|---|
Gender | ||
Female | 1901 (48.6) | 96 (48.0) |
Male | 2010 (51.4) | 104 (52.0) |
Age | ||
<60 years | 150 (3.8) | 2 (1.0) |
≥60 years | 3761 (96.2) | 198 (99.0) |
Medical History | ||
More than two of the following: hypertension, diabetes, coronary artery disease/myocardial infarction, peripheral arterial disease, congestive heart failure, previous stroke, pulmonary disease, hepatic or renal disease | 254 (6.5) | 37 (18.5) |
Concurrent Treatment Amiodarone | 220 (5.6) | 10 (5.0) |
Tobacco Use (within 2 years) | 17 (0.4) | 0 (0) |
Race | N/A | N/A |
HAS-BLED | 1 (1–2) | 2 (1–2) |
CHA2DS2VASc | 3 (2–4) | 3 (2–4) |
Warfarin Care Program (n = 3911) | General Practitioner (n = 200) | |||||
---|---|---|---|---|---|---|
SAMe-TT2R2 Score | Patients | TTR | p-value | Patients | TTR | p-value |
0 | 1646 (42.1) | 80.9 (9.4) | 64 (32.0) | 70.1 (15.4) | ||
1 | 1937 (49.5) | 80.6 (9.5) | p = 0.344 | 109 (54.5) | 68.8 (16.8) | p = 0.775 |
2 | 308 (7.9) | 78.6 (10.4) | p < 0.001 | 27 (13.5) | 63.6 (15.0) | p = 0.061 |
3–4 | 20 (0.5) | 78.0 (14.0) | p = 0.367 | |||
Categorised Score | ||||||
0–1 | 3583 (91.6) | 80.9 (9.5) | 173 (86.5) | 69.3 (16.3) | ||
≥2 | 328 (8.4) | 78.6 (10.7) | p < 0.001 | 27 (13.5) | 63.6 (15.0) | p = 0.089 |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bernaitis, N.; Clark, G.; Kohja, S.; Leong, S.; Anoopkumar-Dukie, S. The SAMe-TT2R2 Score Predicts Warfarin Control in an Australian Population with Atrial Fibrillation. J. Clin. Med. 2019, 8, 882. https://doi.org/10.3390/jcm8060882
Bernaitis N, Clark G, Kohja S, Leong S, Anoopkumar-Dukie S. The SAMe-TT2R2 Score Predicts Warfarin Control in an Australian Population with Atrial Fibrillation. Journal of Clinical Medicine. 2019; 8(6):882. https://doi.org/10.3390/jcm8060882
Chicago/Turabian StyleBernaitis, Nijole, Gemma Clark, Sarah Kohja, Stephanie Leong, and Shailendra Anoopkumar-Dukie. 2019. "The SAMe-TT2R2 Score Predicts Warfarin Control in an Australian Population with Atrial Fibrillation" Journal of Clinical Medicine 8, no. 6: 882. https://doi.org/10.3390/jcm8060882
APA StyleBernaitis, N., Clark, G., Kohja, S., Leong, S., & Anoopkumar-Dukie, S. (2019). The SAMe-TT2R2 Score Predicts Warfarin Control in an Australian Population with Atrial Fibrillation. Journal of Clinical Medicine, 8(6), 882. https://doi.org/10.3390/jcm8060882